for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Grifols To Launch Tavlesse In Europe

Jan 16 (Reuters) - Grifols SA:

* SAYS EUROPEAN COMMISSION HAS APPROVED TAVLESSE (FOSTAMATINIB) FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN ADULT PATIENTS WHO ARE REFRACTORY TO OTHER TREATMENTS

* SAYS GRIFOLS GAINED EXCLUSIVE RIGHTS TO TAVLESSE IN ITP AND OTHER PIPELINE INDICATIONS IN EUROPE AND TURKEY AS A RESULT OF THE COLLABORATION AND LICENSE AGREEMENT REACHED WITH RIGEL PHARMACEUTICALS IN JANUARY 2019

* SAYS TAVLESSE LAUNCH IS EXPECTED TO BE IN Q2 OF THIS YEAR

Source text: bit.ly/30rR772

Further company coverage:

Gdansk Newsroom

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up